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OPINION PAPER
How to conduct research on overdiagnosis. A keynote paper from the
EGPRN May 2016, Tel Aviv
‘Life can only be understood backwards; but it must be lived forwards’ Søren Kierkegaard
(Danish philosopher 1813–1855)
John Brodersena,b,c
aSection of General Practice, Department of Public Health, Faculty of Health Sciences, University of Copenhagen, Denmark; bResearch
Unit for General Practice, Department of Public Health, Faculty of Health Sciences, University of Copenhagen, Denmark; cPrimary
Health Care Research Unit, Region Zealand, Denmark
KEY MESSAGES
 The greatest methodological challenges associated with research on overdiagnosis are that at the individual
level, we can never be sure if the person is overdiagnosed.
 If different methods are used it is possible to investigate different aspects of overdiagnosis, e.g. the experi-
ences, the magnitude and the consequences of overdiagnosis.
ABSTRACT
Overdiagnosis is a growing problem worldwide. Overdiagnosis is the diagnosis of deviations,
abnormalities, risk factors, and pathologies that in themselves would never cause symptoms
(this applies only to risk factors and pathology), would never lead to morbidity, and would never
be the cause of death. Overdiagnosis is often misinterpreted as overutilization or overtreatment.
Overutilization, overtreatment, and overdiagnosis are interrelated but three distinct topics.
Overutilization (establishment of standard practice that does not provide net benefit) does not
have to lead to overdiagnosis or overtreatment, but the risk exists. Treatment of overdiagnosed
conditions is one category of overtreatment. Another is when the best available evidence shows
that the treatment has no beneficial effect. Overdiagnosis can be caused by overutilization and
is nearly always followed by overtreatment. Treating an overdiagnosed condition cannot improve
the patient’s prognosis, and therefore can only be harmful. At the individual level, we can never
be sure if the person is overdiagnosed. However, experiences and thoughts of individuals who
are most likely overdiagnosed can be explored in qualitative interviews, e.g. men with a small
screening detected abdominal aortic aneurism. In longitudinal surveys, the degree and length of
psychosocial consequences associated with overdiagnosis can be estimated. In high-quality RCTs,
the magnitude of overdiagnosis can be quantified, and in cohort studies, we can find indications
of overdiagnosis. Finally, we can conduct research about the consequences of overdiagnosis in
at least eight different areas: financial strain, hassles/inconveniences, medical costs, opportunity
costs, physical harms, psychological harms, societal costs and work-related costs.
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Introduction
The EGPRN arranges biannually a two-day conference
targeting a specific theme. At the EGPRN May 2016
conference in Tel Aviv, the theme was ‘Research on
medical overuse: Overdiagnosis and overtreatment in
family medicine and primary care.’ Overdiagnosis is a
growing problem all over the world, especially in high-
income countries, because of three reasons: (1) over-
detection due to more sensitive tests, more testing,
more screening and earlier diagnosis; (2) widening dis-
ease definitions and lowering of thresholds and; (3)
disease mongering [1]. This paper encompasses the
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themes from a keynote lecture titled ‘How to conduct
research on overdiagnosis’ presented at the EGPRN
meeting in May 2016. Different topics and methodo-
logical issues concerning conducting research on over-
diagnosis are presented and discussed. First,
overdiagnosis is defined and the dilemmas and pitfalls
in all diagnostic processes in a general practitioner’s
(GP’s) clinical practice are described. Second, sugges-
tions of how to conduct research in overdiagnosis
qualitatively and quantitatively are revealed. Finally,
implications for future research are put in perspective.
Definition of overdiagnosis
Overdiagnosis is the diagnosis of deviations, abnormal-
ities, risk factors, and pathologies that in themselves
would never cause symptoms (this applies only to risk
factors and pathology), would never lead to morbidity,
and would never be the cause of death. Treating an
overdiagnosed condition (deviation, abnormality, risk
factor, and pathology) cannot, by definition, improve
the patient’s prognosis, and therefore can only be
harmful [1–3]. Treatment of overdiagnosed conditions
is one category of overtreatment. Another type of
overtreatment is when the best available scientific evi-
dence shows that the treatment has no beneficial
effect on the diagnosed condition and may even be
harmful [4]. Overuse, or better described as overutiliza-
tion, is the ‘establishment of standard practice in
health services or systems that do not provide net
benefit to patients or citizens’ [4]. Overutilization does
not necessarily lead to overdiagnosis or overtreatment,
but the risk increases proportionally with the degree
of overutilization.
The dilemmas and pitfalls of the diagnostic
process in general practice
We can never, as GPs (or patients for that matter), be
certain at the level of the individual patient whether
he or she has in fact been overdiagnosed. Only at the
end of the patient’s life can we for biomedical condi-
tions confirm whether our diagnosis was correct or
iatrogenic.
For psychosocial conditions and illnesses, or mental
disorders, we can never answer that question conclu-
sively. Therefore, the dilemmas and pitfalls in all diag-
nostic processes in a GP’s daily clinical patient-centred
practice—with low prevalence of biomedical diseases
and high prevalence of psychosocial illnesses—is so
succinctly captured by this quote from the Danish
philosopher Søren Kirkegaard (1813–1855): ‘Life can
only be understood backwards; but it must be lived
forwards.’ Hence, the million dollars (or more accur-
ately multi-billion dollars) question: how to conduct
research about something that cannot be directly
observed (overdiagnosis), and yet attempt to reduce
or prevent its prevalence?
How to conduct research on overdiagnosis
Qualitative studies
If we want to know more about ‘lived life’ (e.g., the
experiences and thoughts of individuals that have been
overdiagnosed), we will most likely raise research ques-
tions that can be addressed in qualitative designs, such
as interviews and observational fieldwork. However,
because we can never be certain that the individual has
been overdiagnosed, we can interview those inform-
ants, who are most likely to be overdiagnosed, or
informants that for a short period have had the experi-
ence of being overdiagnosed (false positives).
For example, Reventlow et al. interviewed 16 healthy
women with no chronic or disabling conditions, and
who had been (over)diagnosed with osteoporosis via a
population-based cohort study [5]. The interviews
revealed that the participating women appeared to
take the scan literally. They planned their lives accord-
ingly, believed that the ‘pictures’ revealed some truth,
and interpreted the scan result to mean real fragility,
which they incorporated into their real perception.
Hansson et al. interviewed 15 men who via screen-
ing were (over)diagnosed with an abdominal aortic
aneurism (AAA) with a median aorta-diameter of
32mm [6]. The men expressed ambivalence towards
the diagnosis: ‘they appreciated having the knowledge
but it was accompanied by worry, feelings of anxiety
and existential thoughts about the fragility and finite-
ness of life.’
Brodersen et al. interviewed in a focus group lung
cancer screening participants, who had an abnormal
thorax CT scan that later was confirmed to be false
positive [7]. The critical period from when the abnor-
mal screening result was acknowledged to the point
in time the screening participant was cleared of suspi-
cion of lung cancer was three months or more. These
screening participants reported substantial negative
psychosocial consequences from living with the uncer-
tainty of possibly having lung cancer.
Survey research
We can also conduct longitudinal studies using condi-
tion-specific questionnaires that encompass items
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developed from the qualitative work described above if
we want to address research questions about the
degree to which women are anxious after a false-posi-
tive screening mammography, or how long this anxiety
lasts [8]. A survey using a condition-specific question-
naire for women who had participated in screening
mammography, which included more than 1300
women, revealed that the women still reported substan-
tial negative psychosocial consequences three years
after the false-positive screening mammography [9].
Quantitative studies
Estimating the degree of overdiagnosis by cumulative
incidence. If we are not only interested in the how and
what individuals experience when they have been
overdiagnosed but want to ascertain the number of
people overdiagnosed, then quantitative research
designs are required. The best available scientific evi-
dence is produced through high-quality randomized
controlled trials (RCTs). The next best evidence comes
from cohort studies. The least convincing evidence is
results generated from simulation studies and other
statistical modelling studies not validated with empir-
ical data [10].
The simplest and most robust way of estimating
the degree of overdiagnosis in a screening RCT would
be from the start of screening trial to estimate the
cumulative incidence of the condition screened for in
the control group and the intervention group.
However, two important types of biases are in play,
biases that are normally not included in the standard
bias assessment tools of RCTs. The first is lead-time
bias: the two groups must be followed for a sufficient
time-period after the end of screening. A too short fol-
low-up can otherwise overestimate the degree of over-
diagnosis. In the European randomized study of
screening for prostate cancer, it has for example been
shown that after the nine-year follow-up the ratio
between one prevented death from prostate cancer
and men overdiagnosed with prostate cancer were
1:47, while this ratio decrease to 1:37 at the 11-year
follow-up and 1:27 after 13 years of follow-up [11–13].
The second is contamination bias: if participants in the
control group are either opportunistically screened or
are having some diagnostic work-up for the condition
screened for, then the degree of overdiagnosis can be
underestimated [14]. In the prostate, lung, colorectal,
and ovarian (PLCO) cancer screening trial from the US
more than 80% of the men randomized to the control
group in the PSA-screening part of the trial reported
having undergone at least one PSA test [15]. The
degree of overdiagnosis of prostate cancer in the
PLCO trial was reported to be only 21% while other
RCTs on PSA screening where the control group were
less contaminated with PSA testing reported degrees
of overdiagnosis of 50–63% [16].
In most screening trials and ongoing screening pro-
grammes where the target of the screening is the
actual disease and not precursors, the yearly incidence
of the clinically manifest disease screened for is
around 0.5% and overdiagnosis varies from 10% to
more than 50% depending on the disease screened
for and what screening test is used. Moreover, the
mortality reduction is around 15–30%, again depend-
ing on the disease screened for and which screening
test is used. Thus, small absolute numbers and effect
sizes are in play. This means that even a minor bias in
an RCT can affect these numbers substantially. This is
for example didactically illustrated in the Cochrane
review for screening mammography, where a meta-
analysis including nine RCTs shows a breast cancer
mortality after a 13-year follow-up to be 0.81 (0.74,
0.87) [17]. However, if only the four adequately
randomized trials were included in the meta-analysis,
the estimate was 0.90 (0.79, 1.02) while the estimate
of the five remaining insufficiently randomized trials
were 0.75 (0.67, 0.83) [17]. Hence, including all nine
RCTs shows a 19% statistically significant relative mor-
tality reduction in breast cancer, a statistically signifi-
cant 25% mortality when only the biased trials are
included while including only the non-biased trails
shows a non-statistically significant reduction of 10%.
This illustrates why the need for high-quality RCTs in
medical screening is essential if results on benefits and
harms are to be trusted. However, in most cancer
screening RCTs data on overdiagnosis are not pub-
lished [18]. Therefore, when conducting randomized
controlled screening trials the focus should be not
only on high-quality study design minimizing biases
but also on investigating both the potential intended
positive effects and the potential unintended negative
effects of screening.
Stage shift
Another possible outcome to measure in screening tri-
als that can indicate the degree of overdiagnosis is
stage-shift: a shift to earlier stage at diagnosis.
However, while a relative stage-shift does not tell us if
the screening is benefitting or harming, an absolute
stage-shift is easier to interpret. Esserman and col-
leagues describe in their paper ‘Rethinking screening
for breast cancer and prostate cancer’ three screening
scenarios: optimal, worst case, and intermediate [19].
The didactical clue in Esserman’s paper is that while
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the relative stage-shifts in the three scenarios are the
same, the absolute stage-shifts are very different [19].
An empirical example of this is the Danish lung cancer
screening trial (DLCST). At the end of five yearly
screening rounds, a relative, but not an absolute,
stage-shift was revealed [20]. After five years of follow-
up of the DLCST, the same results were confirmed,
indicating a considerable degree of overdiagnosis in
lung CT screening [21].
Standardized incidence and standardized
mortality
Finally, the trajectory of the standardized incidence
and the standardized mortality of conditions screened
for should be considered, including a time before and
during a screening era. If the standardized incidence
of the condition screened for increases after the start
of screening and the standardized mortality does not
change (and treatment of the condition in the same
period has not improved substantially), this could indi-
cate some degree of overdiagnosis [22]. The magni-
tude of overdiagnosis depends on how much the
incidence of the condition screened for increases.
Moreover, if this increased incidence continues to
increase during the period of screening, or stays con-
sistently elevated at the same increased level after the
end of screening, there is robust evidence of overdiag-
nosis. However, if the increased incidence gradually
stabilizes during screening or the incidence drops after
the period of screening has ended, this is an indication
of a compensatory drop in incidence due to lead-time.
There is no evidence of overdiagnosis if the compen-
satory drop after the end of the screening is just as
great as the increased incidence during the screening
period. Furthermore, when screening for precursors,
the compensatory drop in incidence can be even
greater than the increased incidence during screening,
which then is evidence of a primary preventive effect
of the screening programme [23].
How to calculate the magnitude of
overdiagnosis
The magnitude of overdiagnosis can be estimated in
several ways primarily because different denominators
can be used [24]. Therefore, to compare two or more
estimates of overdiagnosis, it is important to ensure
that the estimates are actually calculating the degree
of overdiagnosis using the same methodology. All
health professionals, politicians, health authorities,
patients, and citizens, in general, have a stake in the
answer to the question: what is the risk of being
overdiagnosed? However, to answer this question, the
denominator or the comparator must be defined. The
risk of being overdiagnosed in cancer screening could
be split into numerous questions, for example, (1) how
many in a cohort invited to screening are overdiag-
nosed with cancer? (2) How many of the screening
participants are overdiagnosed with cancer? (3) How
many of the screening-detected cancers are overdiag-
nosed? (4) How many deaths from cancer are pre-
vented compared to how many screening participants
are overdiagnosed with cancer? The list of questions
can continue. In addition, the answers to these ques-
tions can be communicated in different ways (e.g., as
percentages, percentage points, in absolute numbers,
in odds, etc.). Research about how best to communi-
cate overdiagnosis is in its early stages and more
research is needed [25].
The consequences of overdiagnosis
A final type of research question can focus on the con-
sequences of overdiagnosis. Harris and colleagues
have suggested a taxonomy describing seven different
categories that could be explored: financial strain, has-
sles/inconveniences, medical costs, opportunity costs,
physical harms, psychological harms, and societal costs
[26]. In addition, we have identified empirical evidence
for an additional category: work-related costs [27].
Both qualitative and quantitative study designs are
needed to explore the empirical evidence in these
eight categories of consequences of overdiagnosis.
Implications for research
Overdiagnosis is an extremely harmful and sizeable
problem all over the world and the problem is increas-
ing. This is especially the case in high-income countries
where more sensitive tests, more testing, more screen-
ing and earlier diagnosis occurs and more of the same
will be implemented in the future. Moreover, disease
definitions have been and are still being widened; plus
thresholds for treating risk factors, for example,
have been and are still being lowered. Finally, disease
mongering is growing because it is cheaper and faster
to invent new ‘diseases’ than new pharmaceutical
drugs. In all aspects of overdiagnosis there is a substan-
tial absence of evidence. Therefore, research is needed
into the degree of overdiagnosis; the harm caused by
overdiagnosis; the consequences of overdiagnosis; how
to prevent overdiagnosis; and how to communicate
overdiagnosis to physicians, other healthcare professio-
nals, politicians, healthcare providers and stakeholders,
and most importantly the general population.
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